Selected research
Industry Research
Insulin Glargine and Lispro Industry Research Report 2026
Market perspective
The global Insulin Glargine and Lispro market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Insulin Glargine and Lispro is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Insulin Glargine and Lispro is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Insulin Glargine and Lispro is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Insulin Glargine and Lispro include Sanofi S.A, Merck & Co., Eli Lilly and Company, Wockhardt Ltd., SAJA Pharmaceuticals, Novo Nordisk A/S, Julphar Diabetes LLC, Gan & Lee Pharmaceutical Ltd. and Cipla Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Insulin Glargine and Lispro market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Insulin Glargine and Lispro Market by Company
Sanofi S.A
Merck & Co.
Eli Lilly and Company
Wockhardt Ltd.
SAJA Pharmaceuticals
Novo Nordisk A/S
Julphar Diabetes LLC
Gan & Lee Pharmaceutical Ltd.
Cipla Limited
Biocon Limited
Insulin Glargine and Lispro Segment by Type
Branded Drug
Biosimilar Drug
Insulin Glargine and Lispro Segment by Application
Type I Dibetes
Type II Dibetes
Insulin Glargine and Lispro Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insulin Glargine and Lispro market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insulin Glargine and Lispro and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insulin Glargine and Lispro.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Insulin Glargine and Lispro manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Insulin Glargine and Lispro by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Insulin Glargine and Lispro in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Branded Drug
- Biosimilar Drug
Applications
- Type I Dibetes
- Type II Dibetes
Companies covered
- Sanofi S.A
- Merck & Co.
- Eli Lilly and Company
- Wockhardt Ltd.
- SAJA Pharmaceuticals
- Novo Nordisk A/S
- Julphar Diabetes LLC
- Gan & Lee Pharmaceutical Ltd.
- Cipla Limited
- Biocon Limited
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Insulin Glargine and Lispro Market Size (2021-2032)
- 2.2.2 Global Insulin Glargine and Lispro Sales (2021-2032)
- 2.2.3 Global Insulin Glargine and Lispro Market Average Price (2021-2032)
- 2.3 Insulin Glargine and Lispro by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Branded Drug
- 2.3.3 Biosimilar Drug
- 2.4 Insulin Glargine and Lispro by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Type I Dibetes
- 2.4.3 Type II Dibetes
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Insulin Glargine and Lispro Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Insulin Glargine and Lispro Sales (L) of Manufacturers (2021-2026)
- 3.3 Global Insulin Glargine and Lispro Revenue of Manufacturers (2021-2026)
- 3.4 Global Insulin Glargine and Lispro Average Price by Manufacturers (2021-2026)
- 3.5 Global Insulin Glargine and Lispro Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Insulin Glargine and Lispro, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Insulin Glargine and Lispro, Product Type & Application
- 3.8 Global Manufacturers of Insulin Glargine and Lispro, Established Date
- 3.9 Global Insulin Glargine and Lispro Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi S.A
- 4.1.1 Sanofi S.A Company Information
- 4.1.2 Sanofi S.A Business Overview
- 4.1.3 Sanofi S.A Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi S.A Insulin Glargine and Lispro Product Portfolio
- 4.1.5 Sanofi S.A Recent Developments
- 4.2 Merck & Co.
- 4.2.1 Merck & Co. Company Information
- 4.2.2 Merck & Co. Business Overview
- 4.2.3 Merck & Co. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co. Insulin Glargine and Lispro Product Portfolio
- 4.2.5 Merck & Co. Recent Developments
- 4.3 Eli Lilly and Company
- 4.3.1 Eli Lilly and Company Company Information
- 4.3.2 Eli Lilly and Company Business Overview
- 4.3.3 Eli Lilly and Company Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly and Company Insulin Glargine and Lispro Product Portfolio
- 4.3.5 Eli Lilly and Company Recent Developments
- 4.4 Wockhardt Ltd.
- 4.4.1 Wockhardt Ltd. Company Information
- 4.4.2 Wockhardt Ltd. Business Overview
- 4.4.3 Wockhardt Ltd. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Wockhardt Ltd. Insulin Glargine and Lispro Product Portfolio
- 4.4.5 Wockhardt Ltd. Recent Developments
- 4.5 SAJA Pharmaceuticals
- 4.5.1 SAJA Pharmaceuticals Company Information
- 4.5.2 SAJA Pharmaceuticals Business Overview
- 4.5.3 SAJA Pharmaceuticals Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 SAJA Pharmaceuticals Insulin Glargine and Lispro Product Portfolio
- 4.5.5 SAJA Pharmaceuticals Recent Developments
- 4.6 Novo Nordisk A/S
- 4.6.1 Novo Nordisk A/S Company Information
- 4.6.2 Novo Nordisk A/S Business Overview
- 4.6.3 Novo Nordisk A/S Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Novo Nordisk A/S Insulin Glargine and Lispro Product Portfolio
- 4.6.5 Novo Nordisk A/S Recent Developments
- 4.7 Julphar Diabetes LLC
- 4.7.1 Julphar Diabetes LLC Company Information
- 4.7.2 Julphar Diabetes LLC Business Overview
- 4.7.3 Julphar Diabetes LLC Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Julphar Diabetes LLC Insulin Glargine and Lispro Product Portfolio
- 4.7.5 Julphar Diabetes LLC Recent Developments
- 4.8 Gan & Lee Pharmaceutical Ltd.
- 4.8.1 Gan & Lee Pharmaceutical Ltd. Company Information
- 4.8.2 Gan & Lee Pharmaceutical Ltd. Business Overview
- 4.8.3 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Gan & Lee Pharmaceutical Ltd. Insulin Glargine and Lispro Product Portfolio
- 4.8.5 Gan & Lee Pharmaceutical Ltd. Recent Developments
- 4.9 Cipla Limited
- 4.9.1 Cipla Limited Company Information
- 4.9.2 Cipla Limited Business Overview
- 4.9.3 Cipla Limited Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Cipla Limited Insulin Glargine and Lispro Product Portfolio
- 4.9.5 Cipla Limited Recent Developments
- 4.10 Biocon Limited
- 4.10.1 Biocon Limited Company Information
- 4.10.2 Biocon Limited Business Overview
- 4.10.3 Biocon Limited Insulin Glargine and Lispro Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Biocon Limited Insulin Glargine and Lispro Product Portfolio
- 4.10.5 Biocon Limited Recent Developments
5 Global Insulin Glargine and Lispro Market Scenario by Region
- 5.1 Global Insulin Glargine and Lispro Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Insulin Glargine and Lispro Sales by Region: 2021-2032
- 5.2.1 Global Insulin Glargine and Lispro Sales by Region: 2021-2026
- 5.2.2 Global Insulin Glargine and Lispro Sales by Region: 2027-2032
- 5.3 Global Insulin Glargine and Lispro Revenue by Region: 2021-2032
- 5.3.1 Global Insulin Glargine and Lispro Revenue by Region: 2021-2026
- 5.3.2 Global Insulin Glargine and Lispro Revenue by Region: 2027-2032
- 5.4 North America Insulin Glargine and Lispro Market Facts & Figures by Country
- 5.4.1 North America Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Insulin Glargine and Lispro Sales by Country (2021-2032)
- 5.4.3 North America Insulin Glargine and Lispro Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Insulin Glargine and Lispro Market Facts & Figures by Country
- 5.5.1 Europe Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Insulin Glargine and Lispro Sales by Country (2021-2032)
- 5.5.3 Europe Insulin Glargine and Lispro Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Insulin Glargine and Lispro Market Facts & Figures by Country
- 5.6.1 Asia Pacific Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Insulin Glargine and Lispro Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Insulin Glargine and Lispro Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Insulin Glargine and Lispro Market Facts & Figures by Country
- 5.7.1 South America Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Insulin Glargine and Lispro Sales by Country (2021-2032)
- 5.7.3 South America Insulin Glargine and Lispro Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Insulin Glargine and Lispro Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Insulin Glargine and Lispro Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Insulin Glargine and Lispro Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Insulin Glargine and Lispro Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Insulin Glargine and Lispro Sales by Type (2021-2032)
- 6.1.1 Global Insulin Glargine and Lispro Sales by Type (2021-2032) & (L)
- 6.1.2 Global Insulin Glargine and Lispro Sales Market Share by Type (2021-2032)
- 6.2 Global Insulin Glargine and Lispro Revenue by Type (2021-2032)
- 6.2.1 Global Insulin Glargine and Lispro Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Insulin Glargine and Lispro Revenue Market Share by Type (2021-2032)
- 6.3 Global Insulin Glargine and Lispro Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Insulin Glargine and Lispro Sales by Application (2021-2032)
- 7.1.1 Global Insulin Glargine and Lispro Sales by Application (2021-2032) & (L)
- 7.1.2 Global Insulin Glargine and Lispro Sales Market Share by Application (2021-2032)
- 7.2 Global Insulin Glargine and Lispro Revenue by Application (2021-2032)
- 7.2.1 Global Insulin Glargine and Lispro Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Insulin Glargine and Lispro Revenue Market Share by Application (2021-2032)
- 7.3 Global Insulin Glargine and Lispro Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Insulin Glargine and Lispro Value Chain Analysis
- 8.1.1 Insulin Glargine and Lispro Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Insulin Glargine and Lispro Production Mode & Process
- 8.2 Insulin Glargine and Lispro Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Insulin Glargine and Lispro Distributors
- 8.2.3 Insulin Glargine and Lispro Customers
9 Global Insulin Glargine and Lispro Analyzing Market Dynamics
- 9.1 Insulin Glargine and Lispro Industry Trends
- 9.2 Insulin Glargine and Lispro Industry Drivers
- 9.3 Insulin Glargine and Lispro Industry Opportunities and Challenges
- 9.4 Insulin Glargine and Lispro Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst